Debiopharm Group - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Debiopharm Group - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH1154631D
  • |
  • Pages: 46
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Debiopharm Group (Debiopharm) is a biopharmaceutical company that develops biologics and small molecule drug candidates. The company's product portfolio includes eloxatin, elplat, dacotin, dacplat, decapeptyl, neo decapeptyl, trelstar, pamorelin, salvacyl and moapar, among others. It also offers services such as clinical development, manufacturing and quality assurance, regulatory services and innovative drug delivery and formulation, among others. Debiopharm targets therapy areas include colorectal cancer, ovarian cancer, breast cancer, prostate cancer and other sexual disorders, among others. The company has operations in Switzerland and Canada. Debiopharm is headquartered in Lausanne, Switzerland.

Debiopharm Group - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description - A brief description of the company's operations.

- Key Employees - A list of the key executives of the company.

- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors - A list of the key competitors of the company.

- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Debiopharm Group, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Debiopharm Group, Medical Devices Deals, 2012 to YTD 2018 9

Debiopharm Group, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Debiopharm Group, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

Debiopharm Acquires Antibody Drug Candidate from ImmunoGen 13

Debiopharm International Acquires FibroTrap Sample Processing Technology from Spinomix 14

Debiopharm Group Acquires Antibiotic Clinical Assets and Technology Platform From Affinium 15

Venture Financing 17

ABAC Therapeutics Raises USD20 Million in Series A Financing 17

Immunexpress Raises USD 6 Million In Venture Financing 19

Biocartis Raises USD 40.5 Million In Series E Financing 20

Spinomix Raises USD 3 Million In Series A Financing 22

Biocartis Raises USD 44.7 Million In Series D Financing 23

Partnerships 25

Debiopharm Partners with Merck and Pfizer 25

Debiopharm Enters into Distribution Agreement with Arbor Pharma 26

Debiopharm International Enters into Agreement with EORTC 27

United Labs Enters into Distribution Agreement with Debiopharm International 28

Debiopharm Enters into Agreement with Solid Biosciences 29

Debiopharm Enters into Co-Development Agreement with Nobelex Biotech 30

Atheris Labs Enters Into Agreement With Debiopharm For Debio 0826 Optimization 31

Experimental Therapeutics And Debiopharm Enter Into Agreement To Develop Epigenetic Oncology Target 32

Debiopharm International And TCG Lifesciences Enter Into Research Agreement To Develop Antibiotics 33

Cenix BioScience And Debiopharm Enter Into Agreement To Develop Drug Candidates 34

Debiopharm Enters Into Co-Marketing Agreement With Vifor Pharma For Pamorelin LA And Salvacyl 35

Licensing Agreements 36

Debiopharm International Enters into Licensing Agreement with Almac Discovery 36

Evotec Enters Into Licensing Agreement With Debiopharm 37

Chugai Pharma Enters Into Licensing Agreement With Debiopharm Group For FF284 38

Debiopharm Enters Into Licensing Agreement With Yale University 39

Shasun Pharma Enters Into Licensing Agreement With Debiopharm 40

Debiopharm Enters Into Licensing Agreement With Ascepion Pharma For Kinase Inhibitor, ASP-08126 41

Acquisition 42

Debiopharm To Acquire Pharma Company 42

Debiopharm Group - Key Competitors 43

Debiopharm Group - Key Employees 44

Debiopharm Group - Locations And Subsidiaries 45

Head Office 45

Other Locations & Subsidiaries 45

Appendix 46

Methodology 46

About GlobalData 46

Contact Us 46

Disclaimer 46

List of Figures

Debiopharm Group, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Debiopharm Group, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Debiopharm Group, Medical Devices Deals, 2012 to YTD 2018 9

List of Tables

Debiopharm Group, Pharmaceuticals & Healthcare, Key Facts 2

Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Debiopharm Group, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Debiopharm Group, Deals By Therapy Area, 2012 to YTD 2018 8

Debiopharm Group, Medical Devices Deals, 2012 to YTD 2018 9

Debiopharm Group, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Debiopharm Acquires Antibody Drug Candidate from ImmunoGen 13

Debiopharm International Acquires FibroTrap Sample Processing Technology from Spinomix 14

Debiopharm Group Acquires Antibiotic Clinical Assets and Technology Platform From Affinium 15

ABAC Therapeutics Raises USD20 Million in Series A Financing 17

Immunexpress Raises USD 6 Million In Venture Financing 19

Biocartis Raises USD 40.5 Million In Series E Financing 20

Spinomix Raises USD 3 Million In Series A Financing 22

Biocartis Raises USD 44.7 Million In Series D Financing 23

Debiopharm Partners with Merck and Pfizer 25

Debiopharm Enters into Distribution Agreement with Arbor Pharma 26

Debiopharm International Enters into Agreement with EORTC 27

United Labs Enters into Distribution Agreement with Debiopharm International 28

Debiopharm Enters into Agreement with Solid Biosciences 29

Debiopharm Enters into Co-Development Agreement with Nobelex Biotech 30

Atheris Labs Enters Into Agreement With Debiopharm For Debio 0826 Optimization 31

Experimental Therapeutics And Debiopharm Enter Into Agreement To Develop Epigenetic Oncology Target 32

Debiopharm International And TCG Lifesciences Enter Into Research Agreement To Develop Antibiotics 33

Cenix BioScience And Debiopharm Enter Into Agreement To Develop Drug Candidates 34

Debiopharm Enters Into Co-Marketing Agreement With Vifor Pharma For Pamorelin LA And Salvacyl 35

Debiopharm International Enters into Licensing Agreement with Almac Discovery 36

Evotec Enters Into Licensing Agreement With Debiopharm 37

Chugai Pharma Enters Into Licensing Agreement With Debiopharm Group For FF284 38

Debiopharm Enters Into Licensing Agreement With Yale University 39

Shasun Pharma Enters Into Licensing Agreement With Debiopharm 40

Debiopharm Enters Into Licensing Agreement With Ascepion Pharma For Kinase Inhibitor, ASP-08126 41

Debiopharm To Acquire Pharma Company 42

Debiopharm Group, Key Competitors 43

Debiopharm Group, Key Employees 44

Debiopharm Group, Subsidiaries 45

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Debiopharm Group, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 18130
Site License
USD 500 INR 36260
Corporate User License
USD 750 INR 54390

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com